|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 美国腹腔镜内镜手术协会有关单孔腹腔镜手术的共识显示文摘 | Gill IS Advincula AP Aron M 谢晓峰 朱江帆 | 2010 | 中国微创外科杂志2010，10，11： | 51 |
| 2 | RTOG 0211:a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients显示文摘PURPOSE: To determine the safety and efficacy of gefitinib,an epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor,in combination with radiation for newly diagnosed glioblastoma(GBM) patients.METHODS AND MATERIALS: Between March 21,2002,and May 3,2004,Radiation Therapy Oncology Group(RTOG) 0211 enrolled 31 and 147GBM patients in the phase 1 and 2 arms,respectively.Treatment consisted of daily oral gefinitnib started at the time of conventional cranial radiation therapy(RT) and continued post RT for 18 months or until progression.Tissue microarrays from 68 cases were analyzed for EGFR expression.RESULTS: The maximum tolerated dose(MTD) of gefitinib was determined to be 500 mg in patients on non-enzyme-inducing anticonvulsant drugs(non-EIAEDs).All patients in the phase 2 component were treated at a gefitinib dose of 500 mg;patients receiving EIADSs could be escalated to 750 mg.The most common side effects of gefitinib in combination with radiation were dermatologic and gastrointestinal.Median survival was 11.5 months for patients treated per protocol.There was no overall survival benefit for patients treated with gefitinib + RT when compared with a historical cohort of patients treated with RT alone,matched by RTOG recursive partitioning analysis(RPA) class distribution.Younger age was significantly associated with better outcome.Per protocol stratification,EGFR expression was not found to be of prognostic value for gefitinib + RT-treated patients.CONCLUSIONS: The addition of gefitinib to RT is well tolerated.Median survival of RTOG 0211 patients treated with RT with concurrent and adjuvant gefitinib was similar to that in a historical control cohort treated with radiation alone. | Chakravarti A Wang M Robins HI Lautenschlaeger T Curran WJ Brachman DG Schultz CJ Choucair A Dolled-Filhart M Christiansen J Gustavson M Molinaro A Mischel P Dicker AP Bredel M Mehta M | 2013 | 中国神经肿瘤杂志2013，11，1： | 8 |
| 3 | 固定低剂量三联抗高血压药物与常规治疗对斯里兰卡轻度至中度高血压患者血压控制的疗效差异:一项随机临床试验显示文摘控制不良的高血压是全球领先的公共卫生问题,需要新的治疗策略。该研究评估低剂量三联抗高血压药物治疗是否能达到比常规治疗更好的血压控制。研究者纳入2016年2月至2017年5月在斯里兰卡11所城市医院诊所就诊的需要开始抗高血压治疗(未治疗的患者)或接受单药治疗的患者,进行低剂量三联降压与常规治疗比较的随机、开放性试验,随访至2017年10月。 | Web-ster R Salam A de Silva HA Selak V Stepien S Rajapakse S Amarasekara S Amarasena N Billot L de Silva AP Fernando M Guggilla R Jan S Jayawardena J Maulik PK Mendis S Munasinghe J Naik N Prabhakaran D Ranasinghe G Thom S Tisserra N Senaratne V Wijekoon S Wijeyasingam S Rodgers A Patel A 刘莉 叶鹏 | 2018 | 中华高血压杂志2018，26，12： | 7 |
| 4 | Propylthiouracyl-induced severe liver toxicity:An indication for alanine aminotransferase monitoring?显示文摘Propylthiouracyl (PTU)-related liver toxicity is likely to oc- cur in about 1% of treated patients. In case of acute or subacute hepatitis, liver failure may occur in about one third. We report two further cases of PTU-induced sub- acute hepatitis, in whom the delay between occurrence of liver damage after the initiation of treatment, the un- derestimation of its severity and the delayed withdrawal of the drug were all likely responsible for liver failure. The high incidence of liver toxicity related to PTU, its potential severity and delayed occurrence after initiation of treatment are in favor of monthly alanine aminotrans- ferase monitoring, at least during the first six months of therapy. | M Benyounes C Sempoux C Daumerie J Rahier AP Geubel | 2006 | World Journal of Gastroenterology2006，12，38： | 3 |
| 5 | Trends in treatment and overall survival among patients with proximal esophageal cancer显示文摘BACKGROUND The management of proximal esophageal cancer differs from that of tumors located in the mid and lower part of the esophagus due to the close vicinity of vital structures.Non-surgical treatment options like radiotherapy and definitive chemoradiation(CRT)have been implemented.The trends in(non-)surgical treatment and its impact on overall survival(OS)in patients with proximal esophageal cancer are unclear,related to its rare disease status.To optimize treatment strategies and counseling of patients with proximal esophageal cancer,it is therefore essential to gain more insight through real-life studies.AIM To establish trends in treatment and OS in patients with proximal esophageal cancer.METHODS In this population-based study,patients with proximal esophageal cancer diagnosed between 1989 and 2014 were identified in the Netherlands Cancer Registry.The proximal esophagus consists of the cervical esophagus and the upper thoracic section,extending to 24 cm from the incisors.Trends in radiotherapy,chemotherapy,and surgery,and OS were assessed.Analyses were stratified by presence of distant metastasis.Multivariable Cox proportional hazards regression analyses was performed to assess the effect of period of diagnosis on OS,adjusted for patient,tumor,and treatment characteristics.RESULTS In total,2783 patients were included.Over the study period,the use of radiotherapy,resection,and CRT in non-metastatic disease changed from 53%,23%,and 1%in 1989-1994 to 21%,9%,and 49%in 2010-2014,respectively.In metastatic disease,the use of chemotherapy and radiotherapy increased over time.Median OS of the total population increased from 7.3 mo[95%confidence interval(CI):6.4-8.1]in 1989-1994 to 9.5 mo(95%CI:8.1-10.8)in 2010-2014(logrank P<0.001).In non-metastatic disease,5-year OS rates improved from 5%(95%CI:3%-7%)in 1989-1994 to 13%(95%CI:9%-17%)in 2010-2014(logrank P<0.001).Multivariable regression analysis demonstrated a significant treatment effect over time on survival.In metastatic disease,median OS was 3.8 mo(95%CI:2.5-5.1)in 1989-1994,and 5.1 mo(95%CI:4.3-5.9)in 2010-2014(logrank P=0.26).CONCLUSION OS significantly improved in non-metastatic proximal esophageal cancer,likely to be associated with an increased use of CRT.Patterns in metastatic disease did not change significantly over time. | Judith de Vos-Geelen Sandra ME Geurts Liselot BJ Valkenburg-van Iersel Evelien JM de Jong Vivianne CG Tjan-Heijnen Margreet van Putten Valery EPP Lemmens Heike I Grabsch Nadia Haj Mohammad Frank JP Hoebers Chantal V Hoge Paul M Jeene Hanneke WM van Laarhoven Tom Rozema Marije Slingerland Grard AP Nieuwenhuijzen | 2019 | World Journal of Gastroenterology2019，25，47： | 2 |
| 6 | 强化与标准降压治疗对脑卒中亚型的影响显示文摘在收缩压干预试验(systolic blood pressure intervention trial, SPRINT)中,各治疗组的脑卒中发生比例差异无统计学意义,但脑卒中亚型的病因不同,可能对强化降压治疗的反应不同。SPRINT纳入患者(n=9 361)随机分为目标收缩压<120 mm Hg(1 mm Hg=0.133 kPa)的强化治疗与目标收缩压<140 mm Hg的标准治疗组。 | Wright CB Auchus AP Lerner A Ambrosius WT Ay H Bates JT Chen J Meschia JF Pancholi S Papademetriou V Rastogi A Sweeney M Willard JJ Yee J Oparil S 赵狄(摘译) 郑武洪(审校) | 2021 | 中华高血压杂志2021，29，3： | 2 |
| 7 | Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers显示文摘 | Lindh M Hannoun C Dhillon AP | 1999 | J Infect Dis1999，179，4： | 2 |
| 8 | Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas显示文摘 | Heaney AP Fernando M Yong WH | 2002 | Nat Med2002，8，： | 2 |
| 9 | Cytologic characteristics ofmen ingeal carcinomatosis: increased diagnostic accuracy using carci noembryonic antigenand epithelial membrane antigen immunoocy tochemistry显示文摘 | Jorda M Ganjei AP Nadji M | 1998 | Arch Neurol1998，5，2： | 1 |
| 10 | Spatial normalization of brain images with focal lesions using cost function masking 显示文摘 | Brett M Leff AP Rorden C | 2001 | Neuroimage2001，14，2： | 1 |
| 11 | The waiting game:bridging to paediatric heart transplantation 显示文摘 | Cassidy J de Leval M | 2003 | Lancet2003，362，9400： | 1 |
| 12 | The coronary circulation of the pig heart:comparison with the human heart显示文摘 | Silva AP Agusa | 2005 | Eur J Anat2005，9，2： | 1 |
| 13 | 'Top of the basilar'syndrome and Chagas' disease显示文摘 | Vargas AP Melo M | 2002 | Rev Neural2002，35，4： | 1 |
| 14 | Cystatin C as a marker for glomerular filtration rate in pediatric patients显示文摘 | Ylinen ES Ala Houhala M Harmoinen AP | 2004 | Pediatr Nephrol2004，13，6： | 1 |
| 15 | Indocyanine ￡ reen-assist-ed peeling of the retinal internal lim iting mem brane显示文摘 | Burk SE Da M ata AP Snyder M E | 2000 | Ophthalmolo-gy2000，107，： | 1 |
| 16 | Periodontitis and arthritis interaction in mice involves a shared hypeF inflammatory genotype and functional immunological interferences显示文摘 | Trombone AP Claudino M Colavite P | 2010 | Genes Immun2010，11，6： | 1 |
| 17 | Pathogenesis of chronic urticaria 显示文摘 | Kaplan AP Greaves M | 2009 | Olin Exp Allergy2009，39，6： | 1 |
| 18 | Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types 显示文摘 | Negre AP van Vliet AK Van Erck M | 1997 | Biochim Biophys Acta1997，1345，： | 1 |
| 19 | Salt tolerance coffered by overexpression of a vacuolar Na^+/H^+ antiporter in Arabidopsis显示文摘 | APES M P AHARON G S SNEDDEN W A | 1999 | Science1999，285，： | 1 |
| 20 | Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers显示文摘 | Lindh M Hannoun C Dhillon AP | 1999 | J Infect Dis1999，179，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员